Targeting Drug Resistance 2: RAS Signaling

• 1868 · PDF Resistant cell panel-based discovery of multi-target combinations and mechanisms to overcome KRAS inhibitor resistance Lili Chai, Yue Zhai, Xue Yang, Zhengtai Li, Ying Bi, Yan Zhang, Tj (Tiejun) Bing
• 1869 · PDF Combining FGTI-2734 and MRTX1133 to suppress ERK-driven resistance in KRAS G12D pancreatic cancer Deblina Ghosh, Aslamuzzaman Kazi, Hitesh Kumar Kantilal Vasiyani, Vignesh Vudatha, Nicolas Lecomte, Christine A. Iacobuzio-Donahue, Jose G. Trevino, Said M. Sebti
• 1870 1870 Characterizing drug-induced transcriptional reprogramming in KRAS mutant lung cancer Wafa Malik, Anurag Singh, Laurent Sansregret, Aaron N. Hata
• 1871 · PDF Combined RAS and ICB inhibition targets NF-KB-driven immune evasion in chemoresistant pancreatic cancer Kevin Christian Gulay, Alexei Martsinkovskiy, Isabella Ng, Deepa Sheik Pran Babu, Jay Patel, Rithika Medari, Ponmathi Panneerpandian, Tatiana Hurtado de Mendoza, Andrew Lowy, Herve Tiriac
• 1872 · PDF A high-throughput combination screen identifies NT-1 as a superior compound to overcome KRAS G12D inhibitor resistance Natalie Thielen, Chaoyuan Kuang, Ning Wei, Seiya Kitamura, Emiko Nagai
• 1873 · PDF Atebimetinib's deep cyclic inhibition of MEK constrains MAPK-axis adaptive and acquired alterations in patients with RAS-mutant tumors Jason S. Kim, Jason Funt, Jenny Zhang, Sarah Kolitz, Praveen Nair, Vinny Hayreh, Benjamin J. Zeskind, Igor Matushansky, Brett M. Hall
• 1874 · PDF Prolonged KRAS-MAPK inhibition activates interferon signaling to promote cellular plasticity and uncover novel targets for combination therapy Ashenafi Shiferaw Bulle, Yali Chen, Huaping Li, Hung-Po Chen, Iftikhar Ali Khawar, Lin Li, Yu Wang, Peng Liu, Vikas Kumar Somani, Richard Kurupi, Sapana Prakashrao Bansod, Son Bang Le, Marianna Ruzinova, David D Tran, Kian-Huat Lim
• 1875 · PDF Synergistic co-targeting of KRAS G12V and pan-TEAD by an EGFR-directed, inverted chimeric RNAi molecule Lyla Stanland, Alessandro Porrello, Sarah R. McLarnon, Lori L. O'Brien, Chad V. Pecot
• 1876 · PDF Pre-treatment with azacytidine sensitizes RAS mutated secondary AML to the pan-RAS inhibitor RMC-7977 Xinghan Zeng, Yuju An, Brandy Perkins, Tessa Seale, Erotokritos Georgantzinos, Theodora Chatzilygeroudi, Bogdan Paun, Maximillian Stahl, Mark J. Levis, Styliani Karanika, Alexander Ambinder, Sandra Misale, Theodoros Karantanos
• 1877 · PDF Acquired resistance to Tri-complex inhibitors in colorectal cancer Sabine Jurado, Simone Lieb, Marco H. Hofmann, Mark Pearson, Phillipp Schmalhorst, Krzysztof Zak
• 1878 · PDF Cotargeting B-Raf and ACLY in Ras mutant cells leads to synergistic loss of cell viability and apoptosis Nancy A. Krucher, Bryce D. Aierstok, Sabrina Bergesio, Gabriella J. Galgano, Morgan E. Strecker
• 1879 · PDF Characterization of intrinsic and acquired resistance to KRAS G12C inhibitors across a broad collection of cancer cell line models Jeffrey J. Kooijman, Kirsten J. W. Kevenaar, Imke P. M. Smits, Daphne J. F. Kluitmans, Laura D. R. van Zelst, Bente Timmers, Tsang W. Lam, Jeroen A. D. M. de Roos, Yvonne Grobben, Janneke J. T. M. Melis, Guido J. R. Zaman, Jorg C. J. Benningshof
• 1880 · PDF Deconstructing the paradigm of oncogene cooperation: Targeting MYC to enhance response and overcome resistance to KRAS inhibitors Daniel Capitán-Leo, Íñigo González-Larreategui, Magda Arnal, Judit Grueso, Lorena Sansegundo-Barbosa, Hugo Thabussot, Irene Ferrer, Silvestre Vicent, Marie-Eve Beaulieu, Sílvia Casacuberta-Serra, Laura Soucek
• 1881 · PDF Understanding evolutionary and ecological mechanisms of sotorasib resistance in KRAS G12C-mutant non-small cell lung cancer Jinling Wu, Mina Nguyen Dinh, Arda Durmaz, Maximilian Strobl, Jacob G. Scott
• 1882 · PDF Generation of daraxonrasib-resistant patient-derived xenograft models of pancreatic cancer Nina Dashti-Gibson, Amy L. Olex, Rachel K. Myrick, Alexa M. Barber, David C. Boyd, Emily K. Zboril, Katarzyna M. Tyc, Mikhail G. Dozmorov, Guang-Yu Yang, Nicholas T. Woods, Jose G. Trevino, J. Chuck Harrell
• 1883 · PDF Predicting resistance mechanisms in pancreatic cancer organoids under KRAS G12D inhibition via pooled CRISPR-Cas9 druggable library screen Lauryn E. Flannagan, Michela Cadarso, Md Shahadat Hossan, Molly A. Nellen, Sean J. McIlwain, C. Dustin Rubinstein, Sean Ronnekleiv-Kelly, Jeremy D. Kratz
• 1884 · PDF Molecular determinants of sensitivity and resistance to the pan-RAS(ON) inhibitor daraxonrasib(RMC-6236) across KRAS-mutant patient-derived models Kayla Tyskiewicz, Markus Hippich, Tristan Cates, Gervaise Henry, Gilad Silberberg, Nicole Spanburg, Madeline Westcott, Daniel Ciznadija, Michael Boice, Paul Heverly, Frank Smith, Marianna Zipeto, Stefano Cairo, Sebastian Brabetz
• 1885 · PDF USP7 inhibitor synergistically enhanced the anticancer effect of the KRAS G12C inhibitor by effectively countering feedback signaling pathways​ Yuanyuan Gao, Keqiang Zhang, Wendong Li, Chunxia Su, John Liu, Lilian Gu, Mahima Raul, Dan Raz
• 1886 · PDF Ligand links EGFR reactivation to resistance against KRAS G12C inhibitors in NSCLC Shigeki Nanjo, Yifeng Liu, Hayato Koba, Seiji Yano
• 1887 · PDF Real-time dissection of SCLC emergence in a KRAS G12C LUAD tumour: A case study of targeted therapy resistance Priyanka Gopal
• 1888 · PDF Unveiling mechanisms of MRTX1133 resistance in PDAC models Qin Li
• 1889 · PDF Elucidation and therapeutic strategies to overcome intrinsic resistance mechanisms in KRAS G12D-mutant tumors Ryo Sawada, Tadaaki Yamada, Yuki Katayama, Koichi Takayama
• 1890 · PDF Targeting ribonucleotide reductase to overcome FLT3 inhibitor resistance in acute myeloid leukemia Zhen Tian, Peng Wang, Stacia Octaviani, Yahui Li, Yun Liao, Xiaolei Liu, Zhaorui Lian, Hong Zheng, Elliot Stieglitz, Catherine C. Smith, Jian Huang
• 1891 · PDF Minnelide enhances the antitumor activity of pan-KRAS inhibitor RMC-6236 in preclinical models for pancreatic cancer Edgar Banuelos, Jaeger Moore, Mohana Velagapudi, Ashok Saluja, Daniel D. Von Hoff, Haiyong Han

在会议检索中浏览本分会场